Oncorena treatment for renal cancer

The prognosis for patients with renal (kidney) cancer that has metastasized (spread) is often very poor. Only half of the patients survive more than one to two years. The treatments available today unfortunately only prolong the life with a few months on average and are often attached to severe side-effects.

Oncorena develops a drug based on the natural substance orellanine, a highly kidney selective toxin from certain mushrooms. The therapeutic concept is to treat patients with metastasized renal clear cell cancer in dialysis with orellanine. Hereby the metastases will be destroyed. The ambition is to create a long-term survival benefit for the patients.